Investec Asset Management LTD lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 0.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,701,323 shares of the medical equipment provider’s stock after selling 5,319 shares during the period. Investec Asset Management LTD owned 0.61% of Hologic worth $77,206,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Investec Asset Management North America Inc. increased its holdings in Hologic by 7.0% in the second quarter. Investec Asset Management North America Inc. now owns 23,852 shares of the medical equipment provider’s stock worth $1,082,000 after buying an additional 1,565 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Hologic by 4.4% in the second quarter. PNC Financial Services Group Inc. now owns 207,956 shares of the medical equipment provider’s stock worth $9,435,000 after buying an additional 8,674 shares during the last quarter. ProShare Advisors LLC increased its holdings in Hologic by 11.8% in the second quarter. ProShare Advisors LLC now owns 153,243 shares of the medical equipment provider’s stock worth $6,954,000 after buying an additional 16,119 shares during the last quarter. Profund Advisors LLC increased its holdings in Hologic by 4.4% in the second quarter. Profund Advisors LLC now owns 26,993 shares of the medical equipment provider’s stock worth $1,225,000 after buying an additional 1,132 shares during the last quarter. Finally, Laurion Capital Management LP increased its holdings in Hologic by 837.1% in the second quarter. Laurion Capital Management LP now owns 119,944 shares of the medical equipment provider’s stock worth $5,443,000 after buying an additional 107,144 shares during the last quarter. Hedge funds and other institutional investors own 96.38% of the company’s stock.

In other news, Director Lawrence M. Levy sold 7,139 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total transaction of $278,706.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,594 shares of company stock worth $1,168,871. Company insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Investec Asset Management LTD Reduces Position in Hologic, Inc. (HOLX)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/18/investec-asset-management-ltd-reduces-position-in-hologic-inc-holx.html.

A number of equities analysts recently commented on the company. Jefferies Group LLC restated a “buy” rating and issued a $49.00 price objective on shares of Hologic in a report on Wednesday, June 28th. Bank of America Corporation restated a “neutral” rating and issued a $48.00 price objective (up previously from $44.00) on shares of Hologic in a report on Friday, July 21st. Piper Jaffray Companies restated a “buy” rating and issued a $51.00 price objective on shares of Hologic in a report on Friday, July 14th. Stifel Nicolaus restated a “buy” rating on shares of Hologic in a report on Friday, July 14th. Finally, BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $48.64.

Shares of Hologic, Inc. (NASDAQ HOLX) traded down 0.13% during trading on Monday, reaching $37.67. The company’s stock had a trading volume of 343,920 shares. The company has a market cap of $10.57 billion, a PE ratio of 14.03 and a beta of 0.92. The stock’s 50 day moving average price is $38.90 and its 200 day moving average price is $42.58. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. During the same quarter in the prior year, the business posted $0.51 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. Equities research analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.